Boston criteria

Last updated

The Boston criteria version 2.0 [1] is a set of guidelines designed to diagnose cerebral amyloid angiopathy (CAA), a disease that affects small blood vessels in the brain, particularly those in the cortex and leptomeninges. Although the gold standard for diagnosis is histopathological examination, the Boston criteria provide clinicians with a probabilistic approach for diagnosis largely based on imaging characteristics. [2]

CAA is characterized by the progressive accumulation of a protein called amyloid β in the walls of these blood vessels. CAA is a major cause of lobar intracerebral haemorrhage, which is bleeding in the brain that occurs in the lobes of the brain. CAA is also a contributing factor to age-related cognitive impairment, which is a decline in cognitive function that occurs with aging.

It is important to accurately diagnose CAA during a patient's lifetime because it can affect clinical care and research participation.

Accurate diagnosis can also help researchers enroll appropriate participants in studies aimed at understanding the disease and developing new treatments.

The Boston criteria are intended to provide high diagnostic accuracy with reasonable simplicity, making them useful for both clinical practice and research. The criteria are designed to be applicable across the clinical spectrum of CAA-related presentations, meaning they can be used to diagnose the disease in patients with a variety of symptoms and conditions. The criteria are also intended to be used across clinical settings, meaning they can be applied in different healthcare environments and by different healthcare professionals.

In a study published in 2023, the authors found that the Boston criteria v2.0 substantially increases the proportion of patients with lobar ICH classified as probable CAA in comparison to the Boston criteria v1.5. [3]

Development of the Boston Criteria

Initially, CAA was only defined histopathology as deposition of β-amyloid in the cerebrovasculature. Through the 1980s the disorder was diagnosed in patients with available brain tissue from hematoma evacuation, biopsy, or most commonly post-mortem exam. [4]

The introduction of the imaging-based Boston Criteria in the 1990s marked a significant milestone in the diagnosis of cerebral amyloid angiopathy (CAA). [5] [6] This development enabled the establishment of a diagnosis of probable CAA in living patients without access to brain tissue, effectively shifting the focus from the pathologist's purview to that of the clinician. The implementation of the imaging-based Boston criteria in the 1990s was a significant milestone in the diagnosis of CAA, enabling the diagnosis of probable CAA in living patients without brain tissue access, shifting the focus of diagnosis to clinicians.

The criteria for diagnosing cerebral amyloid angiopathy (CAA) were initially introduced in 1995 through the Methods segment of an analysis of CAA and the apolipoprotein E ε4 allele. [5] This was further elaborated in 1996, where the criteria were presented as a table in a clinical-pathologic case report. [6] These criteria were based on the category terminology that is typically applied to other brain disorders such as Alzheimer's disease. The authors of the criteria defined definite CAA, probable CAA and possible CAA. Definite CAA is diagnosed only through full autopsy, while probable or possible CAA is identified through brain imaging and clinical exclusions. Additionally, there is a category of probable CAA with supporting pathology that is based on clinical scenarios where only limited brain tissue is available for biopsy or hematoma evacuation, as presented in Table 1. In order to avoid diagnosing CAA when the pathology is only mild and incidental, definite CAA requires high neuropathological severity, including features of advanced vasculopathy like amyloid replacement and splitting of the blood vessel wall. [7] For probable CAA with supporting pathology, lesser histopathological severity is required to reflect the smaller amount of sampled tissue and the consequent lower likelihood of identifying the most advanced foci of the disease.

Boston criteria version 2.0 for sporadic cerebral amyloid angiopathy [1]
Definite CAAFull brain post-mortem examination demonstrating:
  • Spontaneous intracerebral haemorrhage, transient focal neurological episodes, convexity subarachnoid haemorrhage, or cognitive impairment or dementia
  • Severe CAA with vasculopathy
  • Absence of other diagnostic lesion
Probable CAA with supporting pathologyClinical data and pathological tissue (evacuated haematoma or cortical biopsy) demonstrating:
  • Presentation with spontaneous intracerebral haemorrhage
  • transient focal neurological episodes, convexity subarachnoid haemorrhage, or cognitive impairment or dementia
  • Some degree of CAA in specimen
  • Absence of other diagnostic lesion
Probable CAAFor patients aged 50 years and older, clinical data and MRI demonstrating:
  • Presentation with spontaneous intracerebral haemorrhage, transient focal neurological episodes, or cognitive impairment or dementia
  • At least two of the following strictly lobar haemorrhagic lesions on T2*-weighted MRI, in any combination: intracerebral haemorrhage, cerebral microbleeds, or foci of cortical superficial siderosis or convexity subarachnoid haemorrhage

OR

One lobar haemorrhagic lesion plus one white matter feature (severe perivascular spaces in the centrum semiovale or white matter hyperintensities in a multispot pattern)†

  • Absence of any deep haemorrhagic lesions (ie, intracerebral haemorrhage or cerebral microbleeds) on T2*-weighted MRI
  • Absence of other cause of haemorrhagic lesions‡
  • Haemorrhagic lesion in cerebellum not counted as either lobar or deep haemorrhagic lesion
Possible CAAFor patients aged 50 years and older, clinical data and MRI demonstrating:
  • Presentation with spontaneous intracerebral haemorrhage, transient focal neurological episodes, or cognitive impairment or dementia
  • Absence of other cause of haemorrhage‡
  • One strictly lobar haemorrhagic lesion on T2*-weighted MRI: intracerebral haemorrhage, cerebral microbleeds, or foci of cortical superficial siderosis or convexity subarachnoid haemorrhage

OR

  • One white matter feature (severe visible perivascular spaces in the centrum semiovale or white matter hyperintensities in a multispot pattern)†
  • Absence of any deep haemorrhagic lesions (ie, intracerebral haemorrhage or cerebral microbleeds) on T2*-weighted MRI • Absence of other cause of haemorrhagic lesions‡
  • Haemorrhagic lesion in cerebellum not counted as either lobar or deep haemorrhagic lesion
CAA=cerebral amyloid angiopathy. †Notable changes from the Boston criteria v1.5. ‡Other causes of haemorrhagic lesion: antecedent head trauma, haemorrhagic transformation of an ischaemic stroke, arteriovenous malformation, haemorrhagic tumour, CNS vasculitis. Other causes of cortical superficial siderosis and acute convexity subarachnoid haemorrhage should also be excluded.

Related Research Articles

<span class="mw-page-title-main">Vascular dementia</span> Dementia resulting from stroke

Vascular dementia is dementia caused by a series of strokes. Restricted blood flow due to strokes reduces oxygen and glucose delivery to the brain, causing cell injury and neurological deficits in the affected region. Subtypes of vascular dementia include subcortical vascular dementia, multi-infarct dementia, stroke-related dementia, and mixed dementia.

<span class="mw-page-title-main">Cerebrovascular disease</span> Condition that affects the arteries that supply the brain

Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the brain and the cerebral circulation. Arteries supplying oxygen and nutrients to the brain are often damaged or deformed in these disorders. The most common presentation of cerebrovascular disease is an ischemic stroke or mini-stroke and sometimes a hemorrhagic stroke. Hypertension is the most important contributing risk factor for stroke and cerebrovascular diseases as it can change the structure of blood vessels and result in atherosclerosis. Atherosclerosis narrows blood vessels in the brain, resulting in decreased cerebral perfusion. Other risk factors that contribute to stroke include smoking and diabetes. Narrowed cerebral arteries can lead to ischemic stroke, but continually elevated blood pressure can also cause tearing of vessels, leading to a hemorrhagic stroke.

<span class="mw-page-title-main">Frontotemporal dementia</span> Types of dementia involving the frontal or temporal lobes

Frontotemporal dementia (FTD), also called frontotemporal degeneration disease or frontotemporal neurocognitive disorder, encompasses several types of dementia involving the progressive degeneration of the brain's frontal and temporal lobes. FTD is the second most prevalent type of early onset dementia after Alzheimer's disease. Men and women appear to be equally affected. FTD generally presents as a behavioral or language disorder with gradual onset. Signs and symptoms tend to appear in late adulthood, typically between the ages of 45 and 65, although it can affect people younger or older than this. Currently, no cure or approved symptomatic treatment for FTD exists, although some off-label drugs and behavioral methods are prescribed.

<span class="mw-page-title-main">Intracranial hemorrhage</span> Hemorrhage, or bleeding, within the skull

Intracranial hemorrhage (ICH), also known as intracranial bleed, is bleeding within the skull. Subtypes are intracerebral bleeds, subarachnoid bleeds, epidural bleeds, and subdural bleeds.

<span class="mw-page-title-main">Cerebral amyloid angiopathy</span> Disease of blood vessels of the brain

Cerebral amyloid angiopathy (CAA) is a form of angiopathy in which amyloid beta peptide deposits in the walls of small to medium blood vessels of the central nervous system and meninges. The term congophilic is sometimes used because the presence of the abnormal aggregations of amyloid can be demonstrated by microscopic examination of brain tissue after staining with Congo red. The amyloid material is only found in the brain and as such the disease is not related to other forms of amyloidosis.

<span class="mw-page-title-main">Primary progressive aphasia</span> Medical condition

Primary progressive aphasia (PPA) is a type of neurological syndrome in which language capabilities slowly and progressively become impaired. As with other types of aphasia, the symptoms that accompany PPA depend on what parts of the left hemisphere are significantly damaged. However, unlike most other aphasias, PPA results from continuous deterioration in brain tissue, which leads to early symptoms being far less detrimental than later symptoms.

<span class="mw-page-title-main">Perivascular space</span>

A perivascular space, also known as a Virchow–Robin space, is a fluid-filled space surrounding certain blood vessels in several organs, including the brain, potentially having an immunological function, but more broadly a dispersive role for neural and blood-derived messengers. The brain pia mater is reflected from the surface of the brain onto the surface of blood vessels in the subarachnoid space. In the brain, perivascular cuffs are regions of leukocyte aggregation in the perivascular spaces, usually found in patients with viral encephalitis.

Pittsburgh compound B (PiB) is a radioactive analog of thioflavin T, which can be used in positron emission tomography scans to image beta-amyloid plaques in neuronal tissue. Due to this property, Pittsburgh compound B may be used in investigational studies of Alzheimer's disease.

<span class="mw-page-title-main">Corticobasal degeneration</span> Rare neurodegenerative disease

Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. CBD symptoms typically begin in people from 50 to 70 years of age, and typical survival before death is eight years. It is characterized by marked disorders in movement and cognition, and is classified as one of the Parkinson plus syndromes. Diagnosis is difficult, as symptoms are often similar to those of other disorders, such as Parkinson's disease, progressive supranuclear palsy, and dementia with Lewy bodies, and a definitive diagnosis of CBD can only be made upon neuropathologic examination.

<span class="mw-page-title-main">McDonald criteria</span>

The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001. These new criteria intended to replace the Poser criteria and the older Schumacher criteria. They have undergone revisions in 2005, 2010 and 2017.

<span class="mw-page-title-main">Intracerebral hemorrhage</span> Type of intracranial bleeding that occurs within the brain tissue itself

Intracerebral hemorrhage (ICH), also known as hemorrhagic stroke, is a sudden bleeding into the tissues of the brain, into its ventricles, or into both. An ICH is a type of bleeding within the skull and one kind of stroke. Symptoms can vary dramatically depending on the severity, acuity, and location (anatomically) but can include headache, one-sided weakness, numbness, tingling, or paralysis, speech problems, vision or hearing problems, memory loss, attention problems, coordination problems, balance problems, dizziness or lightheadedness or vertigo, nausea/vomiting, seizures, decreased level of consciousness or total loss of consciousness, neck stiffness, and fever.

<span class="mw-page-title-main">Intraparenchymal hemorrhage</span> Medical condition

Intraparenchymal hemorrhage (IPH) is one form of intracerebral bleeding in which there is bleeding within brain parenchyma. The other form is intraventricular hemorrhage (IVH).

<span class="mw-page-title-main">Limbic encephalitis</span> Inflammation involving the limbic system in the brain

Limbic encephalitis is a form of encephalitis, a disease characterized by inflammation of the brain. Limbic encephalitis is caused by autoimmunity: an abnormal state where the body produces antibodies against itself. Some cases are associated with cancer and some are not. Although the disease is known as "limbic" encephalitis, it is seldom limited to the limbic system and post-mortem studies usually show involvement of other parts of the brain. The disease was first described by Brierley and others in 1960 as a series of three cases. The link to cancer was first noted in 1968 and confirmed by later investigators.

Behçet's disease is recognized as a disease that cause inflammatory perivasculitis, inflammation of the tissue around a blood or lymph vessel, in practically any tissue in the body. Usually, prevalent symptoms include canker sores or ulcers in the mouth and on the genitals, and inflammation in parts of the eye. In addition, patients experience severe headache and papulopustular skin lesions as well. The disease was first described in 1937 by a Turkish dermatologist, Dr. Hulusi Behçet. Behçet's disease is most prevalent in the Middle East and the Far East regions; however, it is rare in America regions.

Reversible cerebral vasoconstriction syndrome is a disease characterized by a weeks-long course of thunderclap headaches, sometimes focal neurologic signs, and occasionally seizures. Symptoms are thought to arise from transient abnormalities in the blood vessels of the brain. In some cases, it may be associated with childbirth, vasoactive or illicit drug use, or complications of pregnancy. If it occurs after delivery it may be referred to as postpartum cerebral angiopathy.

<span class="mw-page-title-main">Brain positron emission tomography</span> Form of positron emission tomography

Brain positron emission tomography is a form of positron emission tomography (PET) that is used to measure brain metabolism and the distribution of exogenous radiolabeled chemical agents throughout the brain. PET measures emissions from radioactively labeled metabolically active chemicals that have been injected into the bloodstream. The emission data from brain PET are computer-processed to produce multi-dimensional images of the distribution of the chemicals throughout the brain.

Florbetaben, sold under the brand name Neuraceq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is a fluorine-18 (18F)-labeled stilbene derivative.

Familial Danish dementia is an extremely rare, neurodegenerative disease characterized by progressive cataracts, loss of hearing, cerebellar ataxia, paranoid psychosis, and dementia. Neuropathological hallmarks include extensive atrophy of all areas of the brain, chronic diffuse encephalopathy, and the presence of exceedingly thin and nearly totally demyelinated cranial nerves.

Alzheimer's disease (AD) in the Hispanic/Latino population is becoming a topic of interest in AD research as Hispanics and Latinos are disproportionately affected by Alzheimer's Disease and underrepresented in clinical research. AD is a neurodegenerative disease, characterized by the presence of amyloid-beta plaques and neurofibrillary tangles, that causes memory loss and cognitive decline in its patients. However, pathology and symptoms have been shown to manifest differently in Hispanic/Latinos, as different neuroinflammatory markers are expressed and cognitive decline is more pronounced. Additionally, there is a large genetic component of AD, with mutations in the amyloid precursor protein (APP), Apolipoprotein E APOE), presenilin 1 (PSEN1), bridging Integrator 1 (BIN1), SORL1, and Clusterin (CLU) genes increasing one's risk to develop the condition. However, research has shown these high-risk genes have a different effect on Hispanics and Latinos then they do in other racial and ethnic groups. Additionally, this population experiences higher rates of comorbidities, that increase their risk of developing AD. Hispanics and Latinos also face socioeconomic and cultural factors, such as low income and a language barrier, that affect their ability to engage in clinical trials and receive proper care.

Alzheimer's disease (AD) in African Americans is becoming a rising topic of interest in AD care, support, and scientific research, as African Americans are disproportionately affected by AD. Recent research on AD has shown that there are clear disparities in the disease among racial groups, with higher prevalence and incidence in African Americans than the overall average. Pathologies for Alzheimer’s also seem to manifest differently in African Americans, including with neuroinflammation markers, cognitive decline, and biomarkers. Although there are genetic risk factors for Alzheimer’s, these account for few cases in all racial groups.

References

  1. 1 2 Charidimou, Andreas; Boulouis, Gregoire; Frosch, Matthew P; Baron, Jean-Claude; Pasi, Marco; Albucher, Jean Francois; Banerjee, Gargi; Barbato, Carmen; Bonneville, Fabrice; Brandner, Sebastian; Calviere, Lionel; Caparros, François; Casolla, Barbara; Cordonnier, Charlotte; Delisle, Marie-Bernadette (August 2022). "The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study". The Lancet Neurology. 21 (8): 714–725. doi:10.1016/S1474-4422(22)00208-3. PMC   9389452 . PMID   35841910.
  2. ↑ Schroeder, B. E.; Robertson, N. P.; Hughes, T. A. T. (2023-03-24). "Cerebral amyloid angiopathy: an update". Journal of Neurology. 270 (5): 2809–2811. doi:10.1007/s00415-023-11631-3. ISSN   0340-5354. PMC   10130108 . PMID   36961527.
  3. ↑ Du, Yang; Zhang, Wenpeng; Locatelli, Martina; Simister, Robert J.; Jäger, H. Rolf; Werring, David J. (June 2023). "The Boston criteria version 2.0 increase the proportion of lobar intracerebral haemorrhage classified as probable cerebral amyloid angiopathy". Journal of Neurology. 270 (6): 3243–3245. doi:10.1007/s00415-023-11565-w. ISSN   1432-1459. PMID   36656357. S2CID   255973102.
  4. ↑ Vinters, H V (March 1987). "Cerebral amyloid angiopathy. A critical review". Stroke. 18 (2): 311–324. doi: 10.1161/01.str.18.2.311 . ISSN   0039-2499. PMID   3551211.
  5. 1 2 Greenberg, Steven M.; William Rebeck, G.; Vonsattel, Jean Paul G.; Gomez-Isla, Teresa; Hyman, Bradley T. (August 1995). "Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy". Annals of Neurology. 38 (2): 254–259. doi:10.1002/ana.410380219. ISSN   0364-5134. PMID   7654074. S2CID   71022954.
  6. 1 2 "Case Records of the Massachusetts General Hospital (Case 22-1996)". New England Journal of Medicine. 335 (15): 1167. 1996-10-10. doi: 10.1056/nejm199610103351523 . ISSN   0028-4793.
  7. ↑ Vonsattel, Jean Paul G.; Myers, Richard H.; Tessa Hedley-Whyte, E.; Ropper, Allan H.; Bird, Edward D.; Richardson, Edward P. (November 1991). "Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study". Annals of Neurology. 30 (5): 637–649. doi:10.1002/ana.410300503. ISSN   0364-5134. PMID   1763890. S2CID   27787013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.